Results 291 to 300 of about 73,909 (338)
Some of the next articles are maybe not open access.
Journal of Allergy and Clinical Immunology, 1996
respiratory arrest in young patients with asthma. N Engl J Med 1991;324:359-63. 4. Malling HJ. Diagnosis and immunotherapy of mould allergy. Allergy 1986;41:342-50. 5. Beaumont F, Kauffman H, Sluiter H, de Vries K. Sequential sampling of fungal air spores inside and outside the homes of mold-sensitive asthmatic patients: a search for a relationship to ...
Rita A.S. Phaff +3 more
openaire +3 more sources
respiratory arrest in young patients with asthma. N Engl J Med 1991;324:359-63. 4. Malling HJ. Diagnosis and immunotherapy of mould allergy. Allergy 1986;41:342-50. 5. Beaumont F, Kauffman H, Sluiter H, de Vries K. Sequential sampling of fungal air spores inside and outside the homes of mold-sensitive asthmatic patients: a search for a relationship to ...
Rita A.S. Phaff +3 more
openaire +3 more sources
Annals of Allergy, Asthma & Immunology, 1999
Omeprazole is a non-competitive inhibitor of the parietal cell enzyme H+-K--adenosine triphosphatase. To date, two cases of angioedema and urticaria and two cases of anaphylaxis from omeprazole have been published.To report a new patient with omeprazole-induced anaphylaxis demonstrated by skin tests and increased serum tryptase levels.Elevated serum ...
R. Garcia +6 more
openaire +3 more sources
Omeprazole is a non-competitive inhibitor of the parietal cell enzyme H+-K--adenosine triphosphatase. To date, two cases of angioedema and urticaria and two cases of anaphylaxis from omeprazole have been published.To report a new patient with omeprazole-induced anaphylaxis demonstrated by skin tests and increased serum tryptase levels.Elevated serum ...
R. Garcia +6 more
openaire +3 more sources
Human & Experimental Toxicology, 1993
The clinical features and pharmacokinetics of omeprazole in overdose have not previously been described. We report 2 cases. The major clinical features were flushing, tachycardia and headache. Omeprazole pharmacokinetics remained unchanged in overdose.
R E, Ferner, T R, Allison
openaire +2 more sources
The clinical features and pharmacokinetics of omeprazole in overdose have not previously been described. We report 2 cases. The major clinical features were flushing, tachycardia and headache. Omeprazole pharmacokinetics remained unchanged in overdose.
R E, Ferner, T R, Allison
openaire +2 more sources
Omeprazole and the Gastric Mucosa
Digestion, 1990The potential for either omeprazole or its sulphenamide to interact with DNA was investigated by incubating tritiated omeprazole at either neutral or acidic pH with either purified prokaryotic (Escherichia coli) or purified eukaryotic (salmon sperm) DNA. Each incubation was carried out for 30 min.
M Reuben, D Scott, Gary S. Sachs
openaire +2 more sources
Oral pharmacokinetics of omeprazole
European Journal of Clinical Pharmacology, 1984The pharmacokinetics of omeprazole were studied in a group of healthy male subjects after single and repeated oral doses of 30 and 60 mg. Absorption of omeprazole from its enteric-coated formulation was unpredictable. There was a highly significant increase in the area under the plasma concentration time curve (AUC) after repeated dosing.
J. A. H. Forrest +3 more
openaire +3 more sources
Pharmacokinetic comparison of omeprazole capsules and a simplified omeprazole suspension
American Journal of Health-System Pharmacy, 2001The pharmacokinetics of omeprazole delayed-release capsules and a simplified omeprazole suspension (SOS) were studied. Seven healthy volunteers randomly received either one 20-mg omeprazole delayed-release capsule or SOS (omeprazole 20 mg in 10 mL) for seven days before being crossed over to the opposite treatment for seven more days after a two-week ...
RA Quercia +4 more
openaire +3 more sources
Interaction of Clopidogrel and Omeprazole
New England Journal of Medicine, 2010To the Editor: The label for clopidogrel warns physicians to “avoid concomitant use of . . . strong or moderate CYP2C19 inhibitors.” Such inhibitors (e.g., omeprazole) decrease the formation of the active metabolite of clopidogrel, the source of its antiplatelet effects.
Robert Temple, Mary Ross Southworth
openaire +2 more sources
Erythrodermia induced by omeprazole
Int. Journal of Clinical Pharmacology and Therapeutics, 2001To report a case of erythrodermia that appears to be related to the intake of omeprazole (OMP) for treatment of gastroesophageal reflux disease.We describe a case of erythrodermia associated with OMP therapy in a 58-year-old white woman with no predisposing factors.
Navarro-Blasco F +4 more
openaire +3 more sources
The Clinical Safety of Omeprazole
Digestion, 1989This review comprises data from more than 19,000 individuals who have taken part in clinical studies of omeprazole. Isolated, non-specific adverse events which might be attributable to omeprazole have included nausea, dizziness, headache and diarrhoea. These events have been generally mild and transient and have not usually required either a reduction ...
openaire +4 more sources
Pediatric Emergency Care, 2005
Omeprazole; the first proton pump inhibitor (PPI) showing an effective acid inhibitory ability, provides the satisfactory therapy either in gastro-esophageal reflux symptom relief or in healing of erosive esophagitis. It's also effective in peptic ulcer disease. Up to date, omeprazole efficacy and safety are well established in many trials.
Wael El-Matary, Mark Dalzell
openaire +2 more sources
Omeprazole; the first proton pump inhibitor (PPI) showing an effective acid inhibitory ability, provides the satisfactory therapy either in gastro-esophageal reflux symptom relief or in healing of erosive esophagitis. It's also effective in peptic ulcer disease. Up to date, omeprazole efficacy and safety are well established in many trials.
Wael El-Matary, Mark Dalzell
openaire +2 more sources